ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Metrodora Institute, a Leader in Treating Complex Conditions, Chooses the Ivenix Infusion System from Fresenius Kabi

Fresenius Kabi announced today that its Ivenix® Infusion System has been selected by the Metrodora Institute to meet the Institute’s infusion medicine needs. The Metrodora Institute is an integrated, multidisciplinary medical and research center dedicated to treating neuroimmune axis disorders.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230629552234/en/

The Ivenix Infusion System from Fresenius Kabi will be in use at The Metrodora Institute for the Institute's infusion medicine needs. (Photo: Business Wire)

The Ivenix Infusion System from Fresenius Kabi will be in use at The Metrodora Institute for the Institute's infusion medicine needs. (Photo: Business Wire)

“The Ivenix system’s adaptability makes it incredibly easy to use in clinical trials and in providing necessary infusion therapies,” said Shannon Flitton, RN, MSN, clinical operations manager at Metrodora Institute. “The modern system provides our nursing team with a safe, more efficient medication administration process, allowing us to focus on delivering the precise care patients need.”

The Ivenix Infusion System from Fresenius Kabi is designed to overcome deficiencies in other legacy infusion pumps. The patented pumping technology in the Ivenix system delivers critical medications with flow that is continuously measured and controlled to help optimize safety. The pump achieves accurate medication delivery unaffected by external conditions such as bag height, back pressure, and fluid viscosity, and it helps to prevent uncontrolled flow.

“Metrodora is committed to providing the most advanced medical care possible, and the Ivenix Infusion System is another tool to help them do that,” said Eric Sato, vice president of marketing at Fresenius Kabi. ”Simplicity of operation, intelligence, and reliability coupled with adherence to FDA infusion pump guidelines all make Ivenix an ideal choice for advanced medical care.”

The Ivenix Large-Volume Pump includes a large, smartphone-like touchscreen that allows clinicians to automatically program, review, and accept medication orders on the pump. The built-in integration engine supports secure interoperability with leading electronic medical records (EMR) systems and includes tools to automate testing, reducing implementation timelines and resources required to synchronize drug libraries with EMR formularies.

The Ivenix platform also facilitates enterprise-wide, centralized management of the entire pump fleet. This allows for oversight of the infusion pump fleet, including device utilization, location awareness, proactive maintenance, user management, and remote software and security updates—without wasting time hunting and gathering devices.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for patients with critical and chronic conditions. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.

About Metrodora Institute

Metrodora Institute is the first medical and research center dedicated to advancing care and accelerating the path to improved diagnostics, therapeutics, and cures for people living with complex neuroimmune axis disorders. Located in Salt Lake City, UT, the integrated, multidisciplinary institute brings together world-class clinicians, scientists, and engineers under one roof to maximize the impact of scientific discovery and rapidly translate research into better patient outcomes. Metrodora’s comprehensive clinical programs integrate neurology, immunology, and gastroenterology care with genomics, pain management, comprehensive rehabilitation programs, and nutritional and neurocognitive therapies to provide personalized, patient-centered care. Grounded in multidisciplinary collaboration, Metrodora is designed to deliver a new blueprint for healthcare that breaks down barriers between medical specialties and embeds scientific research and discovery directly into patient care. Founded in 2020 by Laura A. Pace, MD, PhD; James Hemp, PhD; and Fidji Simo, CEO of Instacart, Metrodora is leading the next frontier of science and medicine to address a significant unmet medical need. To learn more, visit www.metrodora.co.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.